Pirprofen in acute ocular inflammation: a controlled study.
In a double-blind, between-patient trial, 30 patients affected by acute ocular inflammation were treated with either pirprofen capsules (400 mg twice daily) or indomethacin capsules (50 mg twice daily) for 14 days. Treatment efficacy was evaluated in basal conditions and after 3, 6, 10 and 14 days on the basis of the following criteria: keratic injection, Tyndall phenomenon, vitreous changes, endothelial precipitates and pain severity, all according to 4-point scales. At the end of the study, a final judgement was expressed by the physician. Non-parametric statistical tests showed that both treatments significantly modified all the parameters considered. Both drugs were well tolerated; only 1 patient on pirprofen dropped out because of gastralgia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000627:therapeutic use*; D011897:Random Allocation; D013997:Time Factors; D014606:Uveitis, Anterior / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010666:Phenylpropionates; C008924:pirprofen; D007213:Indomethacin